FDA Warning Letters: Stop Claiming CBD Prevents COVID

By |2022-04-20T07:14:34+01:0020 April 2022|

Once again, the U.S. Food and Drug Administration (FDA) has issued a number of warning letters to companies selling hemp-derived cannabidiol (CBD) products. This time around, the FDA sent these warning letters to companies that had statements on their website claiming CBD is an effective treatment [...]

Comments Off on FDA Warning Letters: Stop Claiming CBD Prevents COVID

An Evaluation of Sample Preparation Techniques for Cannabis Potency Analysis

By |2022-04-20T07:14:21+01:0020 April 2022|

Sample preparation is an essential part of method development and is critical to successful analytical determinations. With cannabis and cannabis products, the analyst is faced with a very challenging matrix and targets that may range from trace level through percent level thus placing considerable demands on [...]

Comments Off on An Evaluation of Sample Preparation Techniques for Cannabis Potency Analysis

How to Navigate Section 280E: Lessons Businesses Can Learn from Recent Court Outcomes

By |2022-04-20T07:14:13+01:0020 April 2022|

The cannabis business landscape is complex and is under constant review and control. Further, rules and regulations from both federal and state governments can pose additional challenges and barriers to business owners. For those unfamiliar, there is a section of Internal Revenue Code, Section 280E, that [...]

Comments Off on How to Navigate Section 280E: Lessons Businesses Can Learn from Recent Court Outcomes